Article Information
History
- December 11, 2021.
Article Versions
- You are currently viewing Version 1 of this article (December 11, 2021 - 21:28).
- Version 2 (February 11, 2022 - 08:18).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Annabel A Powell1,
- Freja Kirsebom1,
- Julia Stowe1,
- Kelsey McOwat1,
- Vanessa Saliba1,
- Mary E Ramsay1,2,
- Jamie Lopez-Bernal1,2,3,
- Nick Andrews1,2,* and
- Shamez N Ladhani1,4,*,†
- 1UK Health Security Agency, London, United Kingdom
- 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
- 3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, United Kingdom
- 4Paediatric Infectious Diseases Research Group, St George’s University of London, London, UK
- ↵† Corresponding author; email: shamez.ladhani{at}phe.gov.uk
Posted December 11, 2021.
Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-19: national test-negative case-control study, England
